Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma

Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma

Abstract Immune checkpoint inhibitor therapy has shown promising results in patients with unresectable hepatocellular carcinoma. This study aimed to evaluate the effectiveness and safety of sintilimab, a programmed cell death protein-1 (PD-1) blockade, combined with sorafenib and transhepatic arteri...

Full description

Bibliographic Details
Main Authors:	Lei Dai, Xingchen Cai, Joseph Mugaanyi, Yelei Liu, Shuqi Mao, Changjiang Lu, Caide Lu
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-10-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-021-98937-2

Similar Items

Preoperative nomogram for microvascular invasion prediction based on clinical database in hepatocellular carcinoma
by: Shuqi Mao, et al.
Published: (2021-07-01)

Author Correction: Preoperative nomogram for microvascular invasion prediction based on clinical database in hepatocellular carcinoma
by: Shuqi Mao, et al.
Published: (2021-10-01)

Recent updates on Sintilimab in solid tumor immunotherapy
by: Xuhong Liu, et al.
Published: (2020-12-01)

Predictive factors for the benefit of triple‐drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma
by: MinKe He, et al.
Published: (2019-08-01)

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
by: Lin Zhang, et al.
Published: (2020-11-01)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
by: Junji Furuse
Published: (2008-11-01)

Nursing management of patients with relapsed or refractory classical Hodgkin's lymphoma treated with sintilimab
by: KUANG Meiling
Published: (2021-01-01)

Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome.
by: Akira Fuchigami, et al.
Published: (2020-01-01)

Therapeutic efficacy and safety of Compound Kushen Injection combined with transarterial chemoembolization in unresectable hepatocellular carcinoma: An update systematic review and meta-analysis
by: Xiao eMa, et al.
Published: (2016-03-01)

Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression
by: Liang Wen, et al.
Published: (2020-08-01)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
by: Yi-Ling Ko, et al.
Published: (2020-04-01)

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
by: Mohamed A. Abd El Aziz, et al.
Published: (2020-10-01)

Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea
by: Myung Ji Goh, et al.
Published: (2021-01-01)

Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study
by: Wenbo Guo MD, et al.
Published: (2020-10-01)

Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
by: Shao W, et al.
Published: (2019-11-01)

Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study
by: Sheng-Long Ye, et al.
Published: (2018-03-01)

Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma
by: Nguyen Van Thai, et al.
Published: (2021-05-01)

Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability toward Adverse Events
by: Hideki Iwamoto, et al.
Published: (2020-04-01)

Outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
by: Hadeel A Helmi, et al.
Published: (2020-01-01)

Unresectable hepatocellular carcinoma: new opportunities and prospects for therapy
by: Dzhamal T Abdurakhmanov, et al.
Published: (2019-06-01)

Y-90 microshperes in the treatment of unresectable hepatocellular carcinoma
by: Al-Kalbani Abdullah, et al.
Published: (2008-01-01)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
by: Personeni N, et al.
Published: (2019-01-01)

Therapeutic strategy in unresectable metastatic colorectal cancer
by: Benoist Chibaudel, et al.
Published: (2012-03-01)

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
by: Francesco Tovoli, et al.
Published: (2021-06-01)

Role of radiofrequency ablation in unresectable hepatocellular carcinoma: An Indian experience
by: Naveen Kalra, et al.
Published: (2013-04-01)

Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma
by: Baojiang Liu, et al.
Published: (2019-05-01)

Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
by: Yuwa Ando, et al.
Published: (2021-08-01)

Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial
by: Haiping Jiang, et al.
Published: (2020-08-01)

Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab
by: Yuankai Shi, et al.
Published: (2020-04-01)

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
by: Breder, V., et al.
Published: (2022)

Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region
by: Colby S. Shemesh, et al.
Published: (2021-06-01)

Factors Predicting Survival after Transarterial Chemoembolization of Unresectable Hepatocellular Carcinoma
by: Farina M. Hanif, et al.
Published: (2014-10-01)

Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib
by: Kei Endo, et al.
Published: (2020-08-01)

Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review.
by: Biao Yang, et al.
Published: (2020-01-01)

Combined versus single locoregional therapy in the treatment of unresectable hepatocellular carcinoma
by: Moustafa H.M. Othman, et al.
Published: (2014-06-01)

Liver Transplantation in the Treatment of Unresectable Hepatocellular Carcinoma in the Absence of Liver Cirrhosis
by: O. D. Olisov, et al.
Published: (2018-09-01)

Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma.
by: Wei-Lun Tsai, et al.
Published: (2014-01-01)

Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study
by: Caiyun Nie, et al.
Published: (2021-09-01)

Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma
by: Chiu SH, et al.
Published: (2020-11-01)

Lenvatinib as the key component of first-line therapy for patients with unresectable hepatocellular carcinoma
by: L. V. Bolotina
Published: (2020-11-01)